These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2899554)

  • 1. Rationale for a new triphasic oral contraceptive.
    Pasquale SA
    Int J Fertil; 1986; 31 SU [UPDATE]():13-9. PubMed ID: 2899554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for a triphasic oral contraceptive.
    Pasquale SA
    J Reprod Med; 1984 Jul; 29(7 Suppl):560-7. PubMed ID: 6481710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone.
    Shoupe D
    Obstet Gynecol; 1994 May; 83(5 Pt 1):679-85. PubMed ID: 8164925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current perspectives on combination oral contraceptives.
    Smith MA; Youngkin EQ
    Clin Pharm; 1984; 3(5):485-96. PubMed ID: 6386284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three triphasic oral contraceptives now available in U.S.
    Contracept Technol Update; 1985 Jan; 6(1):1-2, 4. PubMed ID: 12279912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents.
    Molina RC; Sandoval JZ; Montero AV; Oyarzún PG; Molina TG; González EA
    J Pediatr Adolesc Gynecol; 2009 Feb; 22(1):25-31. PubMed ID: 19232299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives.
    Garceau RJ; Wajszczuk CJ; Kaunitz AM;
    Contraception; 2000 Dec; 62(6):289-95. PubMed ID: 11239615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptives.
    Maclennan AH
    Curr Ther (Seaforth); 1987 Dec; 28(12):113-22. PubMed ID: 12317413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants.
    Schwartz J; Hunt T; Smith WB; Wong P; Larson P; Crumley T; Mehta A; Gottesdiener K; Agrawal N
    J Clin Pharmacol; 2009 Jul; 49(7):807-15. PubMed ID: 19443681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the efficacy and side effects of the contraceptive containing 0.5 mg of norethindrone and 0.1 mg of mestranol in a family planning clinic].
    de Sampaio Júnior LF; Dib JE; Pereira VM; Neme B
    Matern Infanc (Sao Paulo); 1971; 30(1):65-9. PubMed ID: 5135370
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral contraceptives.
    Shearman RP
    Aust Fam Physician; 1984 Sep; 13(9):685-91. PubMed ID: 6508652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of a new low dose combination estrogen and progestogen oral contraceptive: a review of nine clinical studies.
    Woutersz TB
    J Reprod Med; 1975 Sep; 15(3):87-92. PubMed ID: 1214254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The triphasics: insights for effective clinical use.
    Youngkin EQ; Miller LG
    Nurse Pract; 1987 Feb; 12(2):17-8, 23, 26-8. PubMed ID: 3822267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phasic approach to oral contraception: the triphasic concept and its clinical application.
    Upton GV
    Int J Fertil; 1983; 28(3):121-40. PubMed ID: 6140231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The choice of the dose of oestrogen in a combined oral contraceptive.
    Smith M
    Fertil Contracept; 1978 Apr; 2(2):22-3. PubMed ID: 12336093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Triella: a French multicenter double blind clinical study].
    Castaigne JP
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):445-53. PubMed ID: 12280213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
    Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
    Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
    Dieben TO; op ten Berg MT; Coelingh Bennink HJ
    Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
    Gaspard U; Dubois M
    Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.